| abstract |
The present invention provides novel compounds and the use of compounds of the general formula (I), in the form of ligands for melanocortin receptors and / or for the treatment of conditions in the melanocortin system: Where X and Y are chosen regardless of O, N, S and (CH2) n, where n is 0, 1, 2, 3, 4 or 5, or a combination of these and may contain multiple carbon-carbon bonds and branched chains, as well as groups alicyclic and heterocyclic; Q is H or OH; R1 and R2 can be either the same or different and are chosen from hydrogen or the residue of an aromatic group as described in Scheme 1 and the pharmacologically active salts thereof. |